CURR - CURE Pharmaceutical Holding Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
3.3900
+0.2400 (+7.62%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.1500
Open3.1500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.1500 - 3.3900
52 Week Range0.5480 - 4.9000
Volume50,383
Avg. Volume76,129
Market Cap101.261M
Beta (3Y Monthly)4.83
PE Ratio (TTM)N/A
EPS (TTM)-0.4160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE6 days ago

    Uptick Newswire Hosts CURE Pharmaceutical on The Stock Day Podcast to Discuss Major Milestones and 2019 Goals

    PHOENIX, AZ / ACCESSWIRE / April 16, 2019 / Uptick Newswire Stock Day Podcast welcomed CURE Pharmaceutical (CURR) (''the Company''), a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CEO Rob Davidson joined Stock Day host Everett Jolly.

  • GlobeNewswire13 days ago

    United Smart Cities and Cure Pharmaceutical Launch Global Healthcare Awareness Initiative

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced a global healthcare awareness initiative with United Smart Cities for the purpose of educating, informing and providing the next generation healthcare solutions to the world’s 7.3 billion citizens. Recognizing escalating healthcare costs, CURE and United Smart Cities will seek to promote education and innovation in delivering cost-effective and sustainable treatments to the world’s population. “CURE was founded on the principles of affordability and global accessibility of medications,” said Rob Davidson, CEO of Cure Pharmaceutical.  “We are driven to finding healthcare solutions for people of all ages and demographics and we are honored to be in service to this cause with United Smart Cities.

  • GlobeNewswire21 days ago

    CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery

    CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has agreed to acquire Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative delivery systems for a variety of industries, in an all-stock transaction. “This transaction will create a pioneering drug delivery engine with the promise to transform patient experience and wellness,” said Rob Davidson, CEO of CURE Pharmaceutical.

  • GlobeNewswire27 days ago

    CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND (Investigational New Drug) review with the U.S. Food and Drug Administration (FDA). The FDA provided feedback supportive of CURE’s clinical development plans for its CUREfilm Blue, a soluble thin film for oral administration of sildenafil citrate (Viagra™) to treat erectile dysfunction (ED).

  • Benzingalast month

    CURE Pharmaceutical Expands DEA License To Manufacture Cannabinoid Molecules

    CURE Pharmaceutical Holding Corp (OTC: CURR ) said Tuesday it managed to broaden its license from the U.S. Drug Enforcement Administration. The expanded license as an authorized manufacturer of Schedule ...

  • GlobeNewswirelast month

    CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE to take advantage of its latest U.S. Patent No. 10,238,705 issuing this month for the extraction and purification of cannabis plant material, as well as subsequent processing of cannabis extracts for drug formulation. CURE will develop and manufacture cannabis-derived and synthetic cannabidiol-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif.  CUREfilm technology is ideal for the delivery of cannabinoids as it offers increased bioavailability, ease and precision of dosing and greater palatability.

  • GlobeNewswire3 months ago

    National Healthcare Economics and Policy Expert Ruben Jose King-Shaw Jr Joins CURE Pharmaceutical’s Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced Ruben Jose King-Shaw Jr. has joined its Board of Directors. King-Shaw brings significant expertise in healthcare, government and finance. King-Shaw joins the recently named chairman William (Bill) Yuan and Dr. Gene Salkind, expanding the board to six.

  • GlobeNewswire3 months ago

    CURE Pharmaceutical Appoints Chairman, Adds Member to its Board of Directors

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has appointed William (Bill) Yuan to Chairman of the Board and Dr. Gene Salkind to its Board of Directors.

  • GlobeNewswire3 months ago

    CURE Pharmaceutical To Present at Benzinga Cannabis Capital Conference

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will host an investor presentation at the Benzinga Cannabis Capital Conference at the Eden Roc Miami Beach Hotel in Miami on January 16, 2019 at 5pm. “This conference is the ideal kick-off to 2019, which is set to be a landmark year for the cannabis industry,” said Rob Davidson, CEO of CURE Pharmaceutical. If you would like to schedule a meeting with CURE Pharmaceutical, please contact Ashley Ray at aray@olmsteadwilliams.com.

  • GlobeNewswire5 months ago

    CURE Pharmaceutical Secures U.S. DEA Approval to Manufacture Cannabinoid-based Pharmaceuticals

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif. “This license enables CURE to translate the research findings from our collaboration with Technion – Israel Institute of Technology into potential treatments and expand our marketable product lines,” said Jessica Rousset, Chief Operating Officer of CURE Pharmaceutical.

  • GlobeNewswire5 months ago

    CURE Pharmaceutical Names Veteran Executive as Chief Financial Officer

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has tapped Alex Katz to be the company’s Chief Financial Officer. Bringing his expertise in venture capital, Katz will oversee the company’s financial functions and investment relations. “Our company is approaching 2019 amidst exponential growth and a clear vision to be a leader in drug delivery innovation,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical.

  • GlobeNewswire6 months ago

    Prominent Biotech Investor Gene Salkind Adds Another $2M Investment in CURE Pharmaceutical

    CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has announced that the company secured a $2 million investment at $2.5 per share from Gene Salkind, a company advisor and biotech investor, bringing his total investment in the company to $3 million. In February 2018, Dr. Salkind joined CURE’s advisory board to help advance CURE’s pipeline for the central nervous system and other therapeutic areas. “This second round of financing from Dr. Salkind is an example of the confidence our investors see in the company’s future,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical.